Experience in the use of human recombinant erythropoietin (rHuEPO) in cancer patient with anemia
40
Med J Indones
Tambunan
Experience in the Use of Human Recombinant Erythropoietin (rHuEPO) in
Cancer Patient with Anemia
*
Karmel L.Tambunan, Aru Sudoyo, A.Harryanto Reksodiputro
Abstrak
tulang, defsiensi besi,
Anemia pada pendeita kanker dapat disebabkan berbagai faktor seperti toksis sitostatika pada sumsum
asamfol.at,hemolitikdanperdarahan.Anemiaini seringdiserlai'kadareitropoitinyangrelatifkurang. Atasdasarkenyataantersebut
dan menaik*an
di aàs diharapkan pem-berian eitropoietin pada peiderita kanker al 2 gldl and
hematocrit by more than 6 percent (in 80 percent
of cases).
2) Response to treatment was noted at week 2 with
maximum increase bY week 12.
3) In one case with multiple myeloma the patient was
freed from transfusion requirement.
4) Cases with naso-pharyngeal cancer, non-
Hodgkin's lymphoma, and multiple myeloma have
good hop" of attaining a good response with
iffuBpO when the previously mentioned inclusion
criteria were used.
REFERENCES
associated with chronic. disorders' In
Harrison's Principle of Internal Me'dicine 1lù edition' New
York: McGraw Hill 1987.1504-5.
actually seen by the second week. This finding was
t in which resPonse was
l. Bun HF. Anemia
r's inclusion of leukemia
in that study, as the two
patients
and myelodysplastic
entitiés havJ been known to respond poorly to
erythropoetin, the same reason for the exclusion of
puti"ntt in our study' In a review compiled from 12
medical institutions, 616 patients on cancer chemotherapy were studied, in which l27o werc receiving
transiùsions for anemia.8 In this study one patient was
2.
Miller C, Jones RJ, Plantodasi's et al'
5.
t uOwig H, Frizt E, Leitgeb C, Krehner M et al'
Erythropoietin treatment for chronic anemia of selected
studied.T This difference
rendered transfusion-free after THuEPO treatment' The
others reported that treatment with THuEPO reduced
both anemia and transfusion requirement in anemic
patients with cancer'9'
lo
It seems that future studies in the use of erythropoietin
will have to take into consideration factors or
parameters that can influence response'
That
that
pred
of I
Decreased
Eryhtropoietin response in patients with the anemia of cancer. N Eng J Med 1990, 322'1689-92.
3. Abel R. Erythropoietin for Anemia in Cancer Patient : Eur I
Cancer 29 A. SuPPI 2' 1993,52-8'
4. Bowen D, Culligan D, Jacob A. The treatment of anemia in
the myelodysplastic syndrome with recombinant human
erythropoietin. Br J Haematol l99l;77:419-33'
hematological malignancies and solid tumors' Ann Onc
1993,4, 16l-7.
6. Ludwig H, Petcherstorfer M, Leitgeb C, Frizt E' Recombinant Human Erythropoietin for the trreatment of Chronic
Anemia in Multiple Myeloma and Squamous Cell Carcinoma. Stem Cell 1993.; ll: 348-55.
7. Ludwi g H, Lei tgeb C, Frizt E et al. Erythropoietin Treatment
of Chronic Anemia of Cancer. Eur J Cancer 29A' Suppl 2'
1993, S8-S12.
s and found
ant role in
erum levels
increase in
8. Skilling JR, Roger MI, Nabolitz IM et al' An epidemiological review of anemia in cancer chemotherapy in Canada'
European Conference on Clinical Oncology and Cancer
Nursing / European Society of Therapeutic Radiologic Oncology 1995, Paris, Oct 29-Nov 2.
9. Bukowski RM. Clinical efficacy of recombinant
erythropoietin (rHuEPO), in the treatment of anemia associated with cancer. Eryhtropoiesis 1994, 5, 108-14'
10. Henry DH, Abel RI' Recombinant human eryhtropoietin in
of cancer and chemotherapy induced anemia'
result double blind and open labet follow up studies' Semin
the treatment
of cancer involved will have to be taken into consideration. From this study we have drawn these conclusion:
1) The administration of THuEPO in a dose of 150
mg/kg BW in cancer patients undergoing chemo-
Oncol 1994,21, SuPPI 3,21-8-
I
l.
Thatcher N. Predicting the response to THuEPO in anaemic
cancer patients undergoing chemotherapy' Erythropoiesis
I 995;8:99- I 08'
Med J Indones
Tambunan
Experience in the Use of Human Recombinant Erythropoietin (rHuEPO) in
Cancer Patient with Anemia
*
Karmel L.Tambunan, Aru Sudoyo, A.Harryanto Reksodiputro
Abstrak
tulang, defsiensi besi,
Anemia pada pendeita kanker dapat disebabkan berbagai faktor seperti toksis sitostatika pada sumsum
asamfol.at,hemolitikdanperdarahan.Anemiaini seringdiserlai'kadareitropoitinyangrelatifkurang. Atasdasarkenyataantersebut
dan menaik*an
di aàs diharapkan pem-berian eitropoietin pada peiderita kanker al 2 gldl and
hematocrit by more than 6 percent (in 80 percent
of cases).
2) Response to treatment was noted at week 2 with
maximum increase bY week 12.
3) In one case with multiple myeloma the patient was
freed from transfusion requirement.
4) Cases with naso-pharyngeal cancer, non-
Hodgkin's lymphoma, and multiple myeloma have
good hop" of attaining a good response with
iffuBpO when the previously mentioned inclusion
criteria were used.
REFERENCES
associated with chronic. disorders' In
Harrison's Principle of Internal Me'dicine 1lù edition' New
York: McGraw Hill 1987.1504-5.
actually seen by the second week. This finding was
t in which resPonse was
l. Bun HF. Anemia
r's inclusion of leukemia
in that study, as the two
patients
and myelodysplastic
entitiés havJ been known to respond poorly to
erythropoetin, the same reason for the exclusion of
puti"ntt in our study' In a review compiled from 12
medical institutions, 616 patients on cancer chemotherapy were studied, in which l27o werc receiving
transiùsions for anemia.8 In this study one patient was
2.
Miller C, Jones RJ, Plantodasi's et al'
5.
t uOwig H, Frizt E, Leitgeb C, Krehner M et al'
Erythropoietin treatment for chronic anemia of selected
studied.T This difference
rendered transfusion-free after THuEPO treatment' The
others reported that treatment with THuEPO reduced
both anemia and transfusion requirement in anemic
patients with cancer'9'
lo
It seems that future studies in the use of erythropoietin
will have to take into consideration factors or
parameters that can influence response'
That
that
pred
of I
Decreased
Eryhtropoietin response in patients with the anemia of cancer. N Eng J Med 1990, 322'1689-92.
3. Abel R. Erythropoietin for Anemia in Cancer Patient : Eur I
Cancer 29 A. SuPPI 2' 1993,52-8'
4. Bowen D, Culligan D, Jacob A. The treatment of anemia in
the myelodysplastic syndrome with recombinant human
erythropoietin. Br J Haematol l99l;77:419-33'
hematological malignancies and solid tumors' Ann Onc
1993,4, 16l-7.
6. Ludwig H, Petcherstorfer M, Leitgeb C, Frizt E' Recombinant Human Erythropoietin for the trreatment of Chronic
Anemia in Multiple Myeloma and Squamous Cell Carcinoma. Stem Cell 1993.; ll: 348-55.
7. Ludwi g H, Lei tgeb C, Frizt E et al. Erythropoietin Treatment
of Chronic Anemia of Cancer. Eur J Cancer 29A' Suppl 2'
1993, S8-S12.
s and found
ant role in
erum levels
increase in
8. Skilling JR, Roger MI, Nabolitz IM et al' An epidemiological review of anemia in cancer chemotherapy in Canada'
European Conference on Clinical Oncology and Cancer
Nursing / European Society of Therapeutic Radiologic Oncology 1995, Paris, Oct 29-Nov 2.
9. Bukowski RM. Clinical efficacy of recombinant
erythropoietin (rHuEPO), in the treatment of anemia associated with cancer. Eryhtropoiesis 1994, 5, 108-14'
10. Henry DH, Abel RI' Recombinant human eryhtropoietin in
of cancer and chemotherapy induced anemia'
result double blind and open labet follow up studies' Semin
the treatment
of cancer involved will have to be taken into consideration. From this study we have drawn these conclusion:
1) The administration of THuEPO in a dose of 150
mg/kg BW in cancer patients undergoing chemo-
Oncol 1994,21, SuPPI 3,21-8-
I
l.
Thatcher N. Predicting the response to THuEPO in anaemic
cancer patients undergoing chemotherapy' Erythropoiesis
I 995;8:99- I 08'